Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  pegylated arginine deiminase
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-7 of 7 for your search:
Start Over
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: POLARIS2009-001, NCT01287585
Phase I/II Study of ADI-SS PEG 20,000mw in Patients With Advanced Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2005-007, MSKCC IRB #06-165, NYU IRB #07-053, NCT00520299
Testing of ADI-PEG in Hepatocellular Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: 2206, NCT00056992
Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: UMIAMI-20030698, SCCC-2003045, EPROST-20030698, SCCC-20030698, NCT00450372
Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2009-007, Pro00022622, NCT01266018
A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 6837, 2006-004592-35, NCT01279967
ADI-PEG in Patients With Metastatic Melanoma
Phase: Phase I
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: FD-R-2003-01, FD-R-002003-01, NCT00029900
Start Over